Navigation Links
Dr. Jeff Jonas Appointed President of Shire Regenerative Medicine Business and Joins Shire Leadership Team
Date:11/15/2012

LA JOLLA, California, November 15, 2012 /PRNewswire/ --

Shire plc (LSE: SHP, NASDAQ: SHPG), announces that Jeff Jonas M.D. has been appointed President of Shire's Regenerative Medicine (RM) business, effective November 15, 2012.  Jeff will report to Shire Chief Executive, Angus Russell, and will join the Shire Leadership Team.  

After a varied career in research & development, commercial and entrepreneurial business roles, Jeff joined Shire in July 2008 as leader of the Specialty Pharmaceuticals (SP) Research & Development (R&D) team.  

Jeff has been closely involved with the RM business since Shire acquired it as Advanced BioHealing in June 2011.  In addition to his role as head of the SP R&D team, Jeff has been leading the RM R&D team and has been a member of the RM leadership team.  Jeff will lead the newly established RM team to take the business to its next stage of growth.

Jeff's role as head of the SP R&D team will be filled by Arnaud Partiot M.D.  Arnaud is a qualified psychiatrist and has been a senior member of the Shire SP team in various clinical research & development, medical affairs and commercial roles since joining Shire in 2004.

Kevin Rakin, who led Advanced BioHealing Inc. since 2007 and during its integration into Shire, is stepping down from his position as Regenerative Medicine President and from the Shire Leadership Team to pursue new career interests.  Kevin will be available to provide transitional support through 28 December 2012.  

Says Shire Chief Executive, Angus Russell:

"We are pleased with the progress we are making in transforming our Regenerative Medicine business.  Jeff's insight and experience will enable us to build on this as we shape this business for future growth.  We have great ambition for this business and we're co
'/>"/>

SOURCE Shire plc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
2. Elsevier / MEDai Appoints Tom Zajac as New President
3. GenVec President and Chief Executive Officer Announces Retirement
4. Michael A. Marletta Takes Office as New President of Scripps Research Institute
5. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 30th Annual J.P. Morgan Healthcare Conference in San Francisco, CA
6. Selexis SA Appoints Yemi Onakunle as Vice President of Strategic and Market Development
7. Neuralstem President and CEO to Update Ongoing ALS and NSI-189/Major Depressive Disorder Trials at 2012 Biotech Showcase
8. Zyga Technology, Inc. Announces the Appointment of Jim Bullock as President and CEO
9. Cepheid Welcomes Senior Vice President of Human Resources
10. Neuralstem President and CEO to Present at BIO CEO & Investor Conference 2012
11. Hospira Names Zena G. Kaufman Senior Vice President of Quality; Strengthens Quality and Compliance Capabilities With Addition of Top Industry Talent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 2014 /CNW/ - Sunovion Pharmaceuticals Canada Inc. (Sunovion) today ... acetate) for use as a once-daily adjunctive therapy for ... who are not satisfactorily controlled with conventional therapy.  APTIOM ... under 18 years of age. Epilepsy ... according to Epilepsy Canada, it affects 0.6% of the ...
(Date:7/10/2014)... Ouagadougou, Burkina Faso (PRWEB) July 10, 2014 ... Burkina Faso, today have access to an additional ... to increase access to contraception at all levels ... combining a lower-dose formulation of a widely used ... injection system. , Burkina Faso is the first ...
(Date:7/10/2014)... 10, 2014 Understanding the need for ... lines, and the gap that currently exists in this ... its industry-leading portfolio of validated ion channel and GPCR ... cell lines, as ion channels control many critical physiological ... activity creates the potential to treat a variety of ...
(Date:7/10/2014)... 2014 Robert Harman, DVM, Founder and CEO ... proud to announce the relaunch of his highly informative blog, ... series called “ What are Stem Cells ?” Dr. ... straightforward foundation in the basics of stem cell therapy so ... right type of treatment when considering regenerative medicine. , A ...
Breaking Biology Technology:Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 2Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 5Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 6Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3
... - Appointment Enhances Algeta,s Commercial Capabilities ... Cancer , Algeta ASA ... Kay has been appointed as President and Chief,Executive Officer and ... Thomas,Ramdahl will continue as Executive Vice President and Chief Technology,Officer ...
... TUSTIN, Calif., Dec. 11 Peregrine Pharmaceuticals, Inc. (Nasdaq: ... its Board of Directors, unexpectedly passed away on Wednesday. Dr. ... chairman since 2005. At the time of his death, Dr. ... , , "The sudden ...
... Alimera Sciences Inc., a privately held,biopharmaceutical company ... prescription ophthalmic pharmaceuticals, today reported,that enrollment has begun ... and efficacy,of Iluvien(TM) in patients with bilateral geographic ... The pilot ...
Cached Biology Technology:Algeta Appoints Andrew Kay as President and Chief Executive Officer 2Algeta Appoints Andrew Kay as President and Chief Executive Officer 3Algeta Appoints Andrew Kay as President and Chief Executive Officer 4Peregrine Pharmaceuticals Mourns Loss of Chairman Thomas A. Waltz 2Alimera Sciences Begins Pilot Study to Assess Safety and Efficacy of Iluvien(TM) in Patients With Bilateral Geographic Atrophy Due to AMD 2
(Date:7/11/2014)... that cannabinoid receptor type 1 can inhibit ... and reduce neurotransmitter release. However, some scholars ... increase extracellular Ca2+ influx and increase neurotransmitter ... Tongji Hospital Affiliated to Tongji Medical College, ... used whole cell voltage-clamp and calcium imaging ...
(Date:7/11/2014)... of all vertebrates, information is transmitted through synapses, ... signal to be passed from one brain cell ... abundant type of synapse, can be either excitatory ... memory, perception and cognition, and the balance between ... For instance, every time we learn something, ...
(Date:7/10/2014)... NEW YORK , June 27, 2014 /PRNewswire/ ... against Provectus Biopharmaceuticals, Inc. ("Provectus" or the "Company")(NYSE-MKT: ... action, filed in United States District Court, Middle ... Division, is on behalf of a class consisting ... otherwise acquired Provectus securities between December 17, 2013 ...
Breaking Biology News(10 mins):Blame it on the astrocytes 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 3
... shellfish, snails and other animals from the Pacific Ocean ... was interrupted by cooling conditions three million years ago, ... of California, Davis, and Peter Roopnarine at the California ... ice-free Arctic Ocean by 2050. That will restore conditions ...
... Pharmacy researchers have discovered a marine compound off the ... in laboratory tests, a finding they hope will fuel ... disease. The UF-patented compound, largazole, is derived from ... results from early studies today (Aug. 7) at an ...
... The University of Houston department of health and human performance ... a study promoting healthy dietary habits and physical activity. ... of Second Life (SL). , ... is part of the UH Texas Obesity Research Center,s (TORC) ...
Cached Biology News:Pacific shellfish ready to invade Atlantic 2Researchers find cancer-inhibiting compound under the sea 2Researchers find cancer-inhibiting compound under the sea 3TORC at UH turns to virtual world of Second Life for new study 2
XEDAR Antibody...
Xanthine Oxidase (Bovine Buttermilk). Monospecific by IEP. Some cross reactivity with Xanthine Oxidase of other species and tissues may occur....
Rabbit Anti-JNK1/SAPK pan, Polyclonal Antibody...
...
Biology Products: